260 related articles for article (PubMed ID: 27456754)
41. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions.
Sharma BK; Smith CC; Laing JM; Rucker DA; Burnett JW; Aurelian L
Dermatology; 2006; 213(3):192-9. PubMed ID: 17033167
[TBL] [Abstract][Full Text] [Related]
42. [Dysplastic melanocytic nevus].
Salava A; Ranki A; Saksela O
Duodecim; 2010; 126(21):2492-501. PubMed ID: 21171474
[TBL] [Abstract][Full Text] [Related]
43. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
44. Identification of novel deletion Loci at 1p36 and 9p22-21 in melanocytic dysplastic nevi and cutaneous malignant melanomas.
Hussein MR; Roggero E; Tuthill RJ; Wood GS; Sudilovsky O
Arch Dermatol; 2003 Jun; 139(6):816-7. PubMed ID: 12810525
[No Abstract] [Full Text] [Related]
45. The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study.
Walton KE; Garfield EM; Zhang B; Quan VL; Shi K; Mohan LS; Haugh AM; VandenBoom T; Yazdan P; Isales MC; Panah E; Gerami P
J Am Acad Dermatol; 2019 Mar; 80(3):685-693. PubMed ID: 30287318
[TBL] [Abstract][Full Text] [Related]
46. α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Abbas M; Ploch EM; Wehling J; Schipper E; Janciauskiene S; Kreipe HH; Jonigk D
Tumour Biol; 2014 Dec; 35(12):12015-20. PubMed ID: 25149154
[TBL] [Abstract][Full Text] [Related]
47. Proliferative nodule resembling angiomatoid Spitz tumor with degenerative atypia arising within a giant congenital nevus.
Braunberger TL; Adelman M; Shwayder TA; Clarke LE; Friedman BJ
J Cutan Pathol; 2020 Dec; 47(12):1200-1204. PubMed ID: 32776331
[TBL] [Abstract][Full Text] [Related]
48. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue.
Koh SS; Opel ML; Wei JP; Yau K; Shah R; Gorre ME; Whitman E; Shitabata PK; Tao Y; Cochran AJ; Abrishami P; Binder SW
Mod Pathol; 2009 Apr; 22(4):538-46. PubMed ID: 19270649
[TBL] [Abstract][Full Text] [Related]
49. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
Clarke LE; Warf MB; Flake DD; Hartman AR; Tahan S; Shea CR; Gerami P; Messina J; Florell SR; Wenstrup RJ; Rushton K; Roundy KM; Rock C; Roa B; Kolquist KA; Gutin A; Billings S; Leachman S
J Cutan Pathol; 2015 Apr; 42(4):244-52. PubMed ID: 25727210
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
[TBL] [Abstract][Full Text] [Related]
51. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States).
Tran TP; Titus-Ernstoff L; Perry AE; Ernstoff MS; Newsham IF
Cancer Causes Control; 2002 Sep; 13(7):675-82. PubMed ID: 12296515
[TBL] [Abstract][Full Text] [Related]
52. Dysplastic nevi and other risk markers for melanoma.
Seykora J; Elder D
Semin Oncol; 1996 Dec; 23(6):682-7. PubMed ID: 8970587
[TBL] [Abstract][Full Text] [Related]
53. Melanomas, dysplastic nevi and benign nevi: is dysplastic nevus a non-benign neoplasm?
Yus ES; Simon RS
J Cutan Pathol; 2002 Oct; 29(9):570; author reply 570-1. PubMed ID: 12358817
[No Abstract] [Full Text] [Related]
54. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
55. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
56. Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives.
Albert LS; Rhodes AR; Sober AJ
J Am Acad Dermatol; 1990 Jan; 22(1):69-75. PubMed ID: 2298967
[TBL] [Abstract][Full Text] [Related]
57. Congenital melanocytic nevi.
Zayour M; Lazova R
Clin Lab Med; 2011 Jun; 31(2):267-80. PubMed ID: 21549240
[TBL] [Abstract][Full Text] [Related]
58. Nodular lesions arising in a large congenital melanocytic naevus in a newborn with eruptive disseminated Spitz naevi.
Feito-Rodríguez M; de Lucas-Laguna R; Bastian BC; Leboit P; González-Beato MJ; López-Gutiérrez JC; Requena L; Pizarro A
Br J Dermatol; 2011 Nov; 165(5):1138-42. PubMed ID: 21711345
[TBL] [Abstract][Full Text] [Related]
59. The significance of eccentric and central hyperpigmentation, multifocal hyper/hypopigmentation, and the multicomponent pattern in melanocytic lesions lacking specific dermoscopic features of melanoma.
Arevalo A; Altamura D; Avramidis M; Blum A; Menzies S
Arch Dermatol; 2008 Nov; 144(11):1440-4. PubMed ID: 19015418
[TBL] [Abstract][Full Text] [Related]
60. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma.
Clarke LE; Pimentel JD; Zalaznick H; Wang L; Busam KJ
Hum Pathol; 2017 Dec; 70():113-120. PubMed ID: 29079183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
